个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Alectinib in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer as First-Line or Sequential Treatment in China

| 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Yang, X.[1] * ; Dong, X.[2] ; Liu, Y.[3] ; Jin, B.[4] ; Wang, J.[5] ; Wang, Y.[6] ; Zhang, Y.[7] ; Zhuo, M.[1] ; Zhao, J.[1] ;
机构： [1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing/CN [2]Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan/CN, [3]National Cancer Center/national Clinical Research Center for Cancer/ cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing/CN [4]Department of Medical Oncology, The First Hospital, China Medical University, Shenyang/CN [5]Department of Oncology, PLA General Hospital [6]PLA School of Medicine, Beijing/CN, [7]Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijia Zhuang/CN [8]The Oncology Department, The No.1 Hospital of Shijiazhuang, Shijia Zhuang/CN
出处：
ISSN：

关键词： ALK NSCLC Alectinib

语种：
外文
被引次数：
WOS：
中科院分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing/CN
推荐引用方式(GB/T 7714)：
Yang X.,Dong X.,Liu Y.,et al.Alectinib in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer as First-Line or Sequential Treatment in China[J].JOURNAL OF THORACIC ONCOLOGY.2021,16(3):S663-S663.
APA：
Yang, X.,Dong, X.,Liu, Y.,Jin, B.,Wang, J....&Zhao, J..(2021).Alectinib in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer as First-Line or Sequential Treatment in China.JOURNAL OF THORACIC ONCOLOGY,16,(3)
MLA：
Yang, X.,et al."Alectinib in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer as First-Line or Sequential Treatment in China".JOURNAL OF THORACIC ONCOLOGY 16..3(2021):S663-S663

相关文献

[1]eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients [2]ALK Testing in Chinese Advanced NSCLC Patients: A National-Wide Multicenter Prospective Real-World Data Study (The RATICAL Study) [3]A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients [4]The relationship between cerebrospinal fluid metastasis and gene mutations in non-small-cell lung cancer patients [5]More than 40% of Locally Advanced or Metastatic NSCLC Patients Without EGFR/ALK Alterations Have PD-L1 TPS >= 1% in China [6]Crizotinib Versus Chemotherapy On ALK-positive NSCLC: A Systematic Review of Efficacy and Safety [7]EML4-ALK fusion variants associate with gender and age in Chinese NSCLC patients [8]Crizotinib versus chemotherapy on ALK-positive NSCLC: A systematic review of efficacy and safety [9]Efficacy and prognosis of sequential 2G ALK-TKI in ALK-positive advanced NSCLC after crizotinib resistance: A real-world single-center research [10]X-396 用于克唑替尼耐药ALK阳性NSCLC患者的II期研究

资源点击量：39770 今日访问量：0 总访问量：1333 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号